Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening

Value in Health

Volumn 18, Issue 8, 2015, Pages 1138-1151

  O'Mahony, James F ^a,d   Naber, Steffie K ^b   Normand, Charles ^a   Sharp, Linda ^c   O'Leary, John J ^d,e   De Kok, Inge M C M ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

Author keywords

cervical screening; comparator choice; cost effectiveness analysis; model specification

Indexed keywords

ARTICLE; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; EMERGENCY HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; COST BENEFIT ANALYSIS; CYTOLOGY; EARLY CANCER DIAGNOSIS; ECONOMICS; FEMALE; METHODOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES;

VIRUS DNA;

COST-BENEFIT ANALYSIS; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN;

EID: 84951574151     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.09.2939     Document Type: Review

References (65)

1. M.C. Weinstein Principles of cost-effective resource allocation in health care organizations Int J Technol Assess Health Care 6 1990 93 103
2. J.E. Siegel, M.C. Weinstein, and G.W. Torrance Reporting cost-effectiveness studies and results M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
3. M. Weinstein, and R. Zeckhauser Critical ratios and efficient allocation J Public Econ 2 1973 147 157
4. G.W. Torrance, J.E. Siegel, and B.R. Luce Framing and designing the cost-effectiveness analysis M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
5. E. Ləərə, N. Day, and M. Hakama Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes Lancet 329 1987 1247 1249
6. J.J. Kim, M. Brisson, W.J. Edmunds, and et al. Modeling cervical cancer prevention in developed countries Vaccine 26 2008 K76 K86
7. K.M. Elfström, L. Arnheim-Dahlström, L. von Karsa, and et al. Cervical cancer screening in Europe: quality assurance and organisation of programmes Eur J Cancer 51 2015 950 968
8. J. van Rosmalen, I.M. de Kok, and M. van Ballegooijen Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing Br J Obstet Gynaecol 119 2012 699 709
9. A. Anttila, L. von Karsa, A. Aasmaa, and et al. Cervical cancer screening policies and coverage in Europe Eur J Cancer 45 2009 2649 2658
10. W.J. Adriaensen, C. Matheï, F.J. Buntinx, and et al. A framework provided an outline toward the proper evaluation of potential screening strategies J Clin Epidemiol 66 2013 639 647
11. M. Arbyn, G. Ronco, A. Anttila, and et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Vaccine 30 S5 2012 F88 F99
12. J. Cuzick, C. Clavel, K.U. Petry, and et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 2006 1095 1101
13. J. Dillner, M. Rebolj, P. Birembaut, and et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study BMJ 2008 337
14. M. Diaz, S. de Sanjose, J. Ortendahl, and et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain Eur J Cancer 46 2010 2973 2985
15. V.M. Coupé, J.A. Bogaards, C.J. Meijer, and et al. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening Vaccine 30 2012 1813 1822
16. International Monetary Fund World Economic Outlook 2013 International Monetary Fund Washington, DC Available from: http://www.imf.org/external/pubs/ft/weo/2013/01/pdf/text.pdf. [Accessed September 1, 2013]
17. S.L. Kulasingam, J.J. Kim, W.F. Lawrence, and et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS) J Natl Cancer Inst 98 2006 92 100
18. E. Östensson, M. Fröberg, A. Hjerpe, and et al. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden Acta Obstet Gynecol Scand 89 2010 1316 1325
19. A. Lytwyn, J.W. Sellors, J.B. Mahony, and et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation Arch Pathol Lab Med 127 2003 1169 1175
20. B. Cochand-Priollet, I. Cartier, P. de Cremoux, and et al. Cost effectiveness of liquid based cytology with or without hybrid capture II HPV test compared with conventional Pap smears: a study by the French society of clinical cytology Diagn Cytopathol 33 2005 338 343
21. F. Carozzi, S. Cecchini, M. Confortini, and et al. Role of P16 (INK4a) expression in identifying CIN2 or more severe lesions among HPV positive patients referred for colposcopy after abnormal cytology Cancer Cytopathol 108 2006 119 123
22. J. Holmes, L. Hemmett, and S. Garfield The cost-effectiveness of human papillomavirus screening for cervical cancer Eur J Health Econ 6 2005 30 37
23. N. Mühlberger, G. Sroczynski, E. Esteban, and et al. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health Int J Technol Assess Health Care 24 2008 184 192
24. J.F. O'Mahony, J. van Rosmalen, A.G. Zauber, and et al. Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information Med Decis Making 33 2013 407 414
25. N.G. Campos, P.E. Castle, M. Schiffman, and et al. Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL triage study Med Decis Making 32 2012 400 427
26. G. Sroczynski, P. Schnell-Inderst, N. Mühlberger, and et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis Eur J Cancer 47 2011 1633 1646
27. G. Sroczynski, P. Schnell-Inderst, N. Mühlberger, and et al. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany GMS Health Technol Assess 6 2010 1 13
28. M. van Ballegooijen, M. van den Akker-van Marle, P. Warmerdam, and et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-) effectiveness Br J Cancer 76 1997 651 657
29. J.J. Kim, J. Ortendahl, and S.J. Goldie Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States Ann Intern Med 151 2009 538 545
30. J.S. Mandelblatt, W.F. Lawrence, S.M. Womack, and et al. Benefits and costs of using HPV testing to screen for cervical cancer JAMA 287 2002 2372 2381
31. G. Accetta, A. Biggeri, G. Carreras, and et al. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis J Med Screen 17 2010 181 189
32. A. Balasubramanian, S.L. Kulasingam, A. Baer, and et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples J Low Genit Tract Dis 14 2010 185 195
33. J. Berkhof, V.M. Coupé, J.A. Bogaards, and et al. The health and economic effects of HPV DNA screening in The Netherlands Int J Cancer 127 2010 2147 2158
34. J. Berkhof, M.C. de Bruijne, G.D. Zielinski, and et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis Int J Cancer 118 2006 1759 1768
35. M.A. Bidus, G.L. Maxwell, S. Kulasingam, and et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening Obstet Gynecol 107 2006 997 1005
36. P. Bistoletti, K. Sennfält, and J. Dillner Cost-effectiveness of primary cytology and HPV DNA cervical screening Int J Cancer 122 2008 372 376
37. E.A. Burger, J.D. Ortendahl, S. Sy, and et al. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway Br J Cancer 106 2012 1571 1578
38. M.K. Chen, H.F. Hung, S. Duffy, and et al. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination J Eval Clin Pract 17 2011 1050 1058
39. I.H. Chow, C.H. Tang, S.L. You, and et al. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system Br J Cancer 103 2010 1773 1782
40. A. Chuck Cost-effectiveness of 21 alternative cervical cancer screening strategies Value Health 13 2010 169 179
41. V.M. Coupé, H.E. de Melker, P.J. Snijders, and et al. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands Vaccine 27 2009 5111 5119
42. J.D. Goldhaber-Fiebert, N.K. Stout, J.A. Salomon, and et al. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination J Natl Cancer Inst 100 2008 308 320
43. S.J. Goldie, J.J. Kim, and T.C. Wright Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more Obstet Gynecol 103 2004 619 631
44. J.J. Kim, T.C. Wright, and S.J. Goldie Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 287 2002 2382 2390
45. J.J. Kim, T.C. Wright, and S.J. Goldie Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst 97 2005 888 895
46. I.M. de Kok, J. van Rosmalen, J. Dillner, and et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model BMJ 344 2012 e670
47. S.L. Kulasingam, R. Rajan, Y. St Pierre, and et al. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis BMC Med 7 2009 69
48. R. Legood, A. Gray, J. Wolstenholme, and et al. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies BMJ 332 2006 79 85
49. G.L. Maxwell, J.W. Carlson, M. Ochoa, and et al. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries Obstet Gynecol 100 2002 740 748
50. T. Mittendorf, K.U. Petry, T. Iftner, and et al. Economic evaluation of human papillomavirus screening in Germany Eur J Health Econ 4 2003 209 215
51. E. Östensson, A.C. Hellström, K. Hellman, and et al. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program Acta Obstet Gynecol Scand 92 2013 830 840
52. R.M. Rogoza, N. Ferko, J. Bentley, and et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis Vaccine 26 S5 2008 F46 F58
53. C. Sherlaw-Johnson, and Z. Philips An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Br J Cancer 91 2004 84 91
54. A. Vijayaraghavan, M.B. Efrusy, K.A. Goodman, and et al. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening Gynecol Oncol 119 2010 237 242
55. A. Vijayaraghavan, M.B. Efrusy, M.H. Mayrand, and et al. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada Can J Public Health 101 2010 220 225
56. M.E. van den Akker-van, M. van Ballegooijen, G.J. van Oortmarssen, and et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies J Natl Cancer Inst 94 2002 193 204
57. Eurostat. Annual National Accounts 2015. Available from: http://ec.europa.eu/eurostat/web/national-accounts/data/main-tables#. [Accessed July 21, 2015].
58. World Health Organization WHO Commission on Macroeconomics and Health Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health 2001 World Health Organization Geneva
59. V.A. Moyer Screening for cervical cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med 156 2012 880 891
60. Canadian Task Force on Preventive Health Care Recommendations on screening for cervical cancer Can Med Assoc J 185 2013 35 45
61. S. Palmer, and J. Raftery Opportunity cost BMJ 318 1999 1551 1552
62. A. Maynard, and D. McDaid Evaluating health interventions: exploiting the potential Health Policy 63 2003 215 226
63. G. de Bock, K. Vermeulen, L. Jansen, and et al. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness Br J Cancer 108 2013 1579 1586
64. P.P. Woo, J.J. Kim, and G.M. Leung What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol 25 2007 617 624
65. S. Vijan, I. Hwang, J. Inadomi, and et al. The cost-effectiveness of CT colonography in screening for colorectal neoplasia Am J Gastroenterol 102 2007 380 390